TYRA BIOSCIENCES INC (TYRA) Stock Price, Forecast & Analysis
USA - NASDAQ:TYRA - US90240B1061 - Common Stock
TYRA Key Statistics, Chart & Performance
The current stock price of TYRA is 15.48 USD. In the past month the price increased by 1.18%. In the past year, price increased by 0.58%.
TYRA Latest News, Press Relases and Analysis
TYRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About TYRA
Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 60 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Company Info
TYRA BIOSCIENCES INC
2656 State Street
Carlsbad CALIFORNIA US
CEO: Todd Harris
Employees: 60
Phone: 16197284760
TYRA BIOSCIENCES INC / TYRA FAQ
What does TYRA do?
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 60 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
What is the stock price of TYRA BIOSCIENCES INC today?
The current stock price of TYRA is 15.48 USD. The price increased by 2.31% in the last trading session.
Does TYRA BIOSCIENCES INC pay dividends?
TYRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TYRA stock?
TYRA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about TYRA BIOSCIENCES INC (TYRA) stock?
15 analysts have analysed TYRA and the average price target is 32.35 USD. This implies a price increase of 108.97% is expected in the next year compared to the current price of 15.48.
How many employees does TYRA BIOSCIENCES INC have?
TYRA BIOSCIENCES INC (TYRA) currently has 60 employees.
What is the Short Interest ratio of TYRA BIOSCIENCES INC (TYRA) stock?
The outstanding short interest for TYRA BIOSCIENCES INC (TYRA) is 11.43% of its float.
TYRA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TYRA. When comparing the yearly performance of all stocks, TYRA is one of the better performing stocks in the market, outperforming 84.11% of all stocks.
TYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYRA. TYRA has a great financial health rating, but its profitability evaluates not so good.
TYRA Financial Highlights
Over the last trailing twelve months TYRA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS decreased by -16.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.92% | ||
| ROE | -35.03% | ||
| Debt/Equity | 0 |
TYRA Forecast & Estimates
15 analysts have analysed TYRA and the average price target is 32.35 USD. This implies a price increase of 108.97% is expected in the next year compared to the current price of 15.48.